object
compar
differ
igg
antibodi
male
femal
patient
figur
possibl
explan
differ
outcom
male
femal
patient
method
total
number
patient
confirm
infect
enrol
plasma
patient
collect
hospit
detect
igg
antibodi
afterward
differ
igg
antibodi
male
femal
patient
analyz
decemb
acut
respiratori
diseas
caus
unknown
respiratori
syndrom
coronaviru
sarscov
appear
wuhan
china
pneumonia
recent
offici
name
corona
viru
diseas
world
health
organ
incub
time
gener
day
typic
clinic
manifest
fever
cough
short
breath
fatigu
march
confirm
case
dead
case
report
china
patient
develop
mild
gener
symptom
small
part
peopl
progress
sever
critic
diseas
previou
studi
report
male
patient
suscept
develop
sever
symptom
higher
mortal
rate
compar
femal
patient
howev
factor
underli
differ
remain
uncov
date
studi
antibodi
rare
detect
serum
igm
igg
antibodi
ad
new
coronaviru
pneumonia
prevent
control
program
edit
diagnosi
infect
effect
treatment
patient
sever
critic
statu
plasma
donat
recov
patient
contain
high
level
igg
antibodi
use
transfer
treatment
clinic
china
expect
plasma
treatment
brought
signific
attenu
diseas
symptom
indic
igg
antibodi
protect
antibodi
howev
whether
igg
level
exist
differ
male
femal
patient
report
studi
detect
analyz
igg
antibodi
recov
mild
gener
sever
statu
patient
identifi
femal
patient
high
level
igg
antibodi
rel
male
patient
sever
statu
addit
product
igg
antibodi
seem
stronger
femal
patient
earli
phase
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
case
use
studi
deriv
wuhan
union
hospit
tongji
medic
colleg
huazhong
univers
scienc
technolog
gener
inform
clinic
diagnosi
pathogen
diagnosi
patient
extract
electron
medic
record
system
enrol
patient
confirm
case
classifi
new
coronaviru
pneumonia
prevent
control
program
edit
studi
approv
ethic
committe
wuhan
union
hospit
tongji
medic
colleg
huazhong
univers
scienc
technolog
peopl
enrol
studi
sign
inform
consent
form
serum
sampl
collect
healthi
peopl
patient
use
antibodi
detect
igg
antibodi
detect
clia
chemiluminesc
immunoassay
iflash
yhlo
biotechnolog
co
ltd
shenzhen
china
igg
antibodi
detect
kit
cat
yhlo
biotechnolog
co
ltd
shenzhen
china
cutoff
valu
igg
antibodi
oper
strict
accord
manufactur
instruct
studi
graphpad
appli
map
data
statist
analysi
mannwhitney
u
test
use
compar
plasma
igg
antibodi
level
two
group
p
valu
less
consid
statist
signific
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
studi
total
number
hospit
patient
enrol
among
male
femal
patient
respect
patient
contain
three
diseas
sever
statu
mild
gener
sever
recov
patient
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
clarifi
dynam
chang
igg
antibodi
male
femal
patient
analyz
level
igg
antibodi
male
femal
patient
four
diseas
statu
shown
figur
femal
patient
level
igg
antibodi
continu
increas
mild
statu
patient
gener
patient
sever
patient
decreas
recov
patient
male
patient
igg
antibodi
rais
mild
statu
patient
gener
patient
decreas
sever
patient
recov
patient
addit
sever
statu
level
igg
antibodi
three
status
nearli
sever
statu
compar
male
patient
level
igg
antibodi
sever
statu
seem
higher
femal
patient
next
map
scatter
diagram
respect
four
statu
patient
howev
none
four
statu
show
statist
differ
igg
antibodi
level
male
femal
patient
figur
notabl
sever
statu
femal
patient
antibodi
level
male
patient
igg
antibodi
togeth
data
show
igg
level
femal
patient
seem
higher
male
patient
sever
statu
next
determin
concentr
distribut
igg
antibodi
analyz
proport
antibodi
rang
auml
auml
auml
male
patient
femal
patient
shown
figur
proport
rang
auml
consist
male
femal
patient
proport
rang
auml
also
close
male
femal
patient
howev
rang
auml
show
great
differ
two
group
rang
auml
male
patient
account
much
femal
patient
took
rang
auml
femal
patient
account
much
male
patient
occupi
divid
sever
statu
patient
two
group
high
low
level
auml
auml
antibodi
concentr
statist
analysi
show
level
igg
antibodi
femal
patient
statist
differ
male
femal
patient
low
level
group
high
level
group
femal
patient
significantli
higher
male
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
data
suggest
femal
patient
maintain
high
level
igg
antibodi
rel
male
patient
sever
statu
addit
collect
time
inform
case
analyz
differ
igg
level
diseas
onset
result
show
level
igg
antibodi
femal
patient
tend
higher
male
patient
week
diseas
onset
differ
antibodi
disappear
week
diseas
onset
data
indic
gener
igg
antibodi
differ
male
femal
patient
diseas
onset
igg
antibodi
femal
patient
gener
high
level
sever
case
stronger
product
diseas
earli
phase
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
current
new
coronaviru
pneumonia
widespread
mani
countri
world
caus
infect
death
accord
case
report
china
crude
mortal
among
diagnos
patient
show
mild
moder
symptom
good
prognosi
howev
patient
progress
sever
critic
statu
mortal
rate
significantli
increas
high
far
effect
treatment
patient
especi
sever
critic
patient
urgent
distinguish
interfer
advanc
prevent
patient
like
progress
sever
critic
statu
previou
studi
report
high
sever
rate
death
rate
male
patient
rel
femal
patient
howev
possibl
reason
underli
refer
report
product
dynam
igg
antibodi
differ
male
femal
patient
earli
phase
diseas
igg
antibodi
present
stronger
product
femal
patient
sever
statu
contrast
male
igg
antibodi
femal
tend
enrich
high
level
two
phenomena
may
good
reason
explain
differ
outcom
male
femal
patient
howev
exact
mechan
contribut
differ
remain
elus
need
investig
present
convalesc
plasma
consid
potenti
therapi
use
sever
critic
patient
clinic
studi
propos
convalesc
plasma
use
advanc
especi
femal
patient
low
igg
antibodi
long
time
prevent
diseas
progress
sever
critic
statu
convalesc
plasma
avail
addit
studi
also
support
monitor
antibodi
routin
examin
mayb
effici
way
predict
progress
patient
note
limit
studi
firstli
case
collect
signal
hospit
wuhan
union
hospit
sampl
size
rel
small
secondli
critic
case
enrol
studi
thirdli
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
probabl
due
limit
sampl
size
rate
sever
case
male
femal
patient
show
consist
tendenc
previous
report
nevertheless
data
show
studi
reveal
differ
pattern
igg
antibodi
infect
conclus
studi
detect
analyz
igg
antibodi
patient
found
compar
male
patient
femal
patient
maintain
high
level
igg
antibodi
infect
product
igg
femal
patient
tend
stronger
male
patient
earli
phase
propos
doctor
nurs
pay
attent
patient
whose
igg
antibodi
low
level
monitor
igg
antibodi
mayb
potenti
method
assess
progress
author
declar
compet
interest
